journal article·2024-08Open access

TRIM24 Cooperates with Ras Mutation to Drive Glioma Progression through snoRNA Recruitment of PHAX and DNA‐PKcs

Chenxin Xu, Guoyu Chen, Bo Yu, Bowen Sun, Yingwen Zhang, Mingda Zhang, Yi Yang, Yichuan Xiao, Shi‐Yuan Cheng, Yanxin Li, Haizhong Feng

Advanced Science· Volume 11· Issue 29

Abstract

Abstract The factors driving glioma progression remain poorly understood. Here, the epigenetic regulator TRIM24 is identified as a driver of glioma progression, where TRIM24 overexpression promotes HRasV12 anaplastic astrocytoma (AA) progression into epithelioid GBM (Ep‐GBM)‐like tumors. Co‐transfection of TRIM24 with HRasV12 also induces Ep‐GBM‐like transformation of human neural stem cells (hNSCs) with tumor protein p53 gene (TP53) knockdown. Furthermore, TRIM24 is highly expressed in clinical Ep‐GBM specimens. Using single‐cell RNA‐sequencing (scRNA‐Seq), the authors show that TRIM24 overexpression impacts both intratumoral heterogeneity and the tumor microenvironment. Mechanically, HRasV12 activates phosphorylated adaptor for RNA export (PHAX) and upregulates U3 small nucleolar RNAs (U3 snoRNAs) to recruit Ku‐dependent DNA‐dependent protein kinase catalytic subunit (DNA‐PKcs). Overexpressed TRIM24 is also recruited by PHAX to U3 snoRNAs, thereby facilitating DNA‐PKcs phosphorylation of TRIM24 at S767/768 residues. Phosphorylated TRIM24 induces epigenome and transcription factor network reprogramming and promotes Ep‐GBM‐like transformation. Targeting DNA‐PKcs with the small molecule inhibitor NU7441 synergizes with temozolomide to reduce Ep‐GBM tumorigenicity and prolong animal survival. These findings provide new insights into the epigenetic regulation of Ep‐GBM‐like transformation and suggest a potential therapeutic strategy for patients with Ep‐GBM.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Glioma Diagnosis and Treatment · RNA modifications and cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Systems Medicine for Cancer Renji‐Med X Clinical Stem Cell Research Center Ren Ji Hospital Shanghai Cancer Institute School of Medicine Shanghai Jiao Tong University Shanghai 200127 China

Pediatric Translational Medicine Institute Department of Hematology & Oncology Shanghai Children's Medical Center School of Medicine Shanghai Jiao Tong University National Health Committee Key Laboratory of Pediatric Hematology & Oncology Shanghai 200127 China

CAS Key Laboratory of Tissue Microenvironment and Tumor Shanghai Institute of Nutrition and Health University of Chinese Academy of Sciences Chinese Academy of Sciences Shanghai 200031 China

Department of Neurology Lou and Jean Malnati Brain Tumor Institute The Robert H. Lurie Comprehensive Cancer Center Simpson Querrey Institute for Epigenetics Northwestern University Feinberg School of Medicine Chicago IL 60611 USA

Funding

National Natural Science Foundation of China · Program of Shanghai Academic Research Leader · Natural Science Foundation of Shanghai Municipality

References (80)

Show source-provided references
1. 10.1093/neuonc/noaa10610.1093/neuonc/noaa106 ↗
2. 10.1038/nrc391810.1038/nrc3918 ↗
3. 10.1001/jama.2023.002310.1001/jama.2023.0023 ↗
4. 10.1126/science.125425710.1126/science.1254257 ↗
5. 10.1016/j.cell.2019.06.02410.1016/j.cell.2019.06.024 ↗
6. 10.1038/nrc326110.1038/nrc3261 ↗
7. 10.1016/j.ccell.2022.10.00210.1016/j.ccell.2022.10.002 ↗
8. 10.1093/neuonc/not08410.1093/neuonc/not084 ↗
9. 10.1093/hmg/ddr19210.1093/hmg/ddr192 ↗
10. 10.1038/nrc210910.1038/nrc2109 ↗
11. 10.1038/sj.onc.120145510.1038/sj.onc.1201455 ↗
12. Mayrhofer M. · Dis. Models Mech. · 2016 · 10 · 15
13. 10.1172/JCI6381110.1172/JCI63811 ↗
14. 10.1016/j.ccell.2022.08.01410.1016/j.ccell.2022.08.014 ↗
15. 10.1038/s41467-021-25650-z10.1038/s41467-021-25650-z ↗
16. 10.1093/emboj/20.9.214010.1093/emboj/20.9.2140 ↗
17. 10.1038/nrc313910.1038/nrc3139 ↗
18. 10.1038/nature0954210.1038/nature09542 ↗
19. 10.1038/s41568-020-0290-x10.1038/s41568-020-0290-x ↗
20. 10.1016/j.ccell.2016.04.01210.1016/j.ccell.2016.04.012 ↗
21. 10.1093/neuonc/noaa13810.1093/neuonc/noaa138 ↗
22. 10.1038/s41467-017-01731-w10.1038/s41467-017-01731-w ↗
23. 10.1128/MCB.01705-1210.1128/MCB.01705-12 ↗
24. 10.1038/s41467-019-12384-210.1038/s41467-019-12384-2 ↗
25. 10.1158/0008-5472.CAN-21-175610.1158/0008-5472.CAN-21-1756 ↗
26. 10.1093/nar/gkac56410.1093/nar/gkac564 ↗
27. 10.1016/j.molcel.2020.12.01510.1016/j.molcel.2020.12.015 ↗
28. 10.1038/s41586-020-2041-210.1038/s41586-020-2041-2 ↗
29. 10.1126/scitranslmed.abc727510.1126/scitranslmed.abc7275 ↗
30. 10.1093/neuonc/noac10510.1093/neuonc/noac105 ↗
31. 10.1007/s00401-016-1545-110.1007/s00401-016-1545-1 ↗
32. 10.1111/bpa.1256610.1111/bpa.12566 ↗
33. 10.1016/j.wneu.2019.08.00710.1016/j.wneu.2019.08.007 ↗
34. 10.1111/nan.1209310.1111/nan.12093 ↗
35. Yukihiko Sonoda T. O. · Cancer Res. · 2001 · 61 · 4956
36. 10.1158/0008-5472.CAN-09-390910.1158/0008-5472.CAN-09-3909 ↗
37. 10.1111/bpa.1257210.1111/bpa.12572 ↗
38. 10.1097/PAS.0b013e31827f9c5e10.1097/PAS.0b013e31827f9c5e ↗
39. 10.1007/s10014-021-00407-010.1007/s10014-021-00407-0 ↗
40. 10.1016/j.ccell.2017.06.00310.1016/j.ccell.2017.06.003 ↗
41. 10.1016/j.immuni.2014.06.00810.1016/j.immuni.2014.06.008 ↗
42. 10.1182/blood-2018-11-84454810.1182/blood-2018-11-844548 ↗
43. 10.1016/j.molcel.2013.01.03810.1016/j.molcel.2013.01.038 ↗
44. 10.1016/j.cell.2013.09.05310.1016/j.cell.2013.09.053 ↗
45. 10.1038/nrg368210.1038/nrg3682 ↗
46. 10.1080/21655979.2020.186049110.1080/21655979.2020.1860491 ↗
47. 10.1016/j.canlet.2022.21604210.1016/j.canlet.2022.216042 ↗
48. 10.1038/s41573-020-0068-610.1038/s41573-020-0068-6 ↗
49. 10.1186/s13045-021-01127-w10.1186/s13045-021-01127-w ↗
50. 10.1038/nrd428110.1038/nrd4281 ↗
51. 10.1016/j.bcp.2011.12.02910.1016/j.bcp.2011.12.029 ↗
52. 10.1080/15548627.2019.171043010.1080/15548627.2019.1710430 ↗
53. 10.1016/S1470-2045(21)00578-710.1016/S1470-2045(21)00578-7 ↗
54. 10.1146/annurev.biochem.052308.09313110.1146/annurev.biochem.052308.093131 ↗
55. 10.1038/onc.2017.37710.1038/onc.2017.377 ↗
56. 10.1016/j.molcel.2004.11.01210.1016/j.molcel.2004.11.012 ↗
57. 10.1016/j.molcel.2004.11.01310.1016/j.molcel.2004.11.013 ↗
58. 10.1016/S0092-8674(00)80829-610.1016/S0092-8674(00)80829-6 ↗
59. 10.1128/MCB.01189-0710.1128/MCB.01189-07 ↗
60. 10.1038/s41392-021-00567-710.1038/s41392-021-00567-7 ↗
61. Wang S. · Int. J. Clin. Exp. Pathol. · 2020 · 13 · 1529
62. 10.3390/brainsci1304063310.3390/brainsci13040633 ↗
63. 10.1007/s10014-014-0192-210.1007/s10014-014-0192-2 ↗
64. 10.1158/0008-5472.CAN-19-368210.1158/0008-5472.CAN-19-3682 ↗
65. 10.1200/JCO.21.0284010.1200/JCO.21.02840 ↗
66. 10.1016/j.brainres.2020.14724710.1016/j.brainres.2020.147247 ↗
67. 10.1038/s41467-018-07475-510.1038/s41467-018-07475-5 ↗
68. 10.1186/s13046-017-0489-110.1186/s13046-017-0489-1 ↗
69. 10.1097/CAD.000000000000113010.1097/CAD.0000000000001130 ↗
70. 10.1111/bpa.1288710.1111/bpa.12887 ↗
71. 10.1186/s40478-019-0774-710.1186/s40478-019-0774-7 ↗
72. 10.1177/1073274821104001310.1177/10732748211040013 ↗
73. 10.1016/j.currproblcancer.2020.10070110.1016/j.currproblcancer.2020.100701 ↗
74. 10.3390/ijms1904109010.3390/ijms19041090 ↗
75. 10.1073/pnas.081317710610.1073/pnas.0813177106 ↗
76. 10.1016/j.immuni.2021.02.00310.1016/j.immuni.2021.02.003 ↗
77. 10.1126/sciadv.abf430410.1126/sciadv.abf4304 ↗
78. 10.1172/JCI7309310.1172/JCI73093 ↗
79. 10.1093/neuonc/noz10710.1093/neuonc/noz107 ↗
80. 10.1038/onc.2013.19810.1038/onc.2013.198 ↗